The end of service and support date for the Philips Respironics Trilogy Evo platform, which includes Trilogy Evo and Trilogy EV300, has been extended from January 25, 2029 to January 31, 2031. This means that Trilogy Evo platform devices currently with customers will have service and support through January 31, 2031.

An option to rework affected Trilogy 100/200 devices is now available to US customers. This means that customers now have the option to select either rework or financial compensation in exchange for affected Trilogy devices.


Philips Respironics will contact ventilation customers with more information and actions for customers. If you have any questions, please reach out to [email protected].

Some Trilogy 100/200 and V60/V60 Plus users impacted by Philips Respironics recalls may be using the Trilogy Evo platform of ventilators as an alternative. Please be aware of recent important product updates related to the Trilogy Evo platform of devices.


Software updates have been issued to address several previously-communicated issues.


For software installation instructions and to confirm that you are using the latest version of software, please click here.

Philips Respironics has become aware of a potential issue when using in-line nebulizers in certain configurations with Trilogy Evo, Trilogy Evo O2, Trilogy Evo Universal (US) and Trilogy EV300 devices. The use of in-line nebulizers placed in certain locations can result in aerosol deposits accumulating over time on the device’s internal flow sensor. Impacted flow sensors may result in inaccurate flow measurements in certain circumstances. For more information including under what circumstances this issue can occur as well as actions for customers, please click here.

To learn how to properly set up an in-line nebulizer with the Trilogy Evo platform of ventilators when using a passive, active PAP, active flow or dual-limb circuit, click here.

In March 2023 Philips Respironics issued a medical device recall regarding interruptions and/or loss of therapy in the Philips Respironics OmniLab Advanced Plus (OLA+), V30 Auto, BiPAP A30, and BiPAP A40. The affected products feature a Ventilator Inoperative alarm, which occurs when the ventilator detects an internal error or a condition that could result in interruption and/or loss of therapy.

Providing patients with safe and high-quality therapy devices is our primary focus. We encourage you to read the Interruptions and/or loss of therapy due to Ventilation Inoperative Alarm Medical Device Recall below to learn more about the circumstances under which this issue can occur and the mitigating actions you can take to ensure safe continued use.

We continue to work on remediation pathways for affected Trilogy 100/200 devices. Business customers (i.e., Durable Medical Equipment providers, hospitals and other institutions) now have the option to select financial compensation in exchange for their affected Trilogy 100/200 devices, instead of waiting for remediation via technical/service correction once available.


The financial compensation amount per device will be based on the age of the device at the time of the recall announcement (June 14, 2021). If you elect financial compensation, you must work directly with Philips Respironics to make the election and coordinate the return of your affected device(s). The device(s) must be returned and received by Philips Respironics in order for the financial compensation to be issued.


Business customers with affected Trilogy 100/200 devices will receive a communication from Philips Respironics containing a Trilogy Information Request Form for electing the financial compensation option. In the interim, if you have any questions on the financial compensation option please contact [email protected].

Ozone and UV light cleaning products are not currently approved cleaning methods for sleep apnea devices, ventilators, or masks and should not be used.